. Author manuscript; available in PMC: 2014 Sep 12.

Published in final edited form as: Gynecol Oncol. 2009 Oct 17;116(1):61–65. doi: 10.1016/j.ygyno.2009.09.018

Table 1.

Schema of dual-resistance model

	Primary Treatment Group (4 drugs)⁺		Secondary Treatment group (9 drugs)⁺⁺
	Platinum	Taxane	Gemcitabine	Topotecan	Doxil
Dual-resistance	EDR	LDR	EDR	IDR	LDR
Non-resistance	IDR	LDR	IDR	IDR	LDR

Dual-resistance was defined as the presence of EDR in both groups. Non-resistance was defined as absence of EDR in both groups.

⁺

First group included cisplatin, carboplatin, paclitaxel, and docetaxel.

⁺⁺

Second group included cyclophosphamide, doxil, doxorubicin, etoposide, fluorouracil, gemcitabine, gemcitabin with cisplatin, ifosamide, and topotecan (schematically 2 and 3 drugs are shown in each group, respectively).

Abbreviations: EDR, extreme drug resistance; IDR, intermediate drug resistance; and LDR, low drug resistance.